FORE adds $67.4M as targeted cancer therapy advances
FORE Biotherapeutics’ expanded Series D-2 shows specialist biotech capital concentrating around programmes that have moved beyond discovery into later-stage clinical development.
Biotech investors are still writing large cheques, but increasingly for companies that have crossed from platform promise into harder clinical validation.
What happened
FORE Biotherapeutics closed an upsized $67.4M Series D-2 extension, taking the total Series D-2 financing to $110M.
The new financing was co-led by SR One, Medicxi and SymBiosis, with additional new and existing investors participating.
FORE is developing targeted cancer therapies and has highlighted progress around plixorafenib, its lead programme.
Why it matters
This is a useful biotech-market signal because the company is operating much closer to the registration and commercialisation phase than an early discovery startup.
At that stage, the risk profile changes. Investors are underwriting trial execution, regulatory evidence, patient selection and eventual market access rather than only the scientific platform.
The size and composition of the syndicate suggest that specialist capital remains available when oncology programmes reach more advanced validation points.
The bigger picture
Biotech funding is becoming more selective rather than disappearing.
Companies with credible clinical progress can still raise substantial rounds, while earlier and less differentiated programmes face a tougher market. FORE’s financing reflects that concentration of capital around assets with clearer development paths.